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Abstract
Objective. To analyse the medicines prescription, prescrip-
tion filling, payment expenditure for medicines by ambula-
tory health service users (HSU) in 2006, and to evaluate its 
evolution in the last 12 years. Material and Methods. Using 
data from the National Health Surveys in 2006 three binary 
logistic regression models were constructed to identify the 
variables associated with the prescription rate, prescription 
filling and payment for medicines in 2006. The results of ac-
cess to medicines were compared to the ones from previous 
National Health Services from 1994 and 2000. Results. The 
type of health service provider was found to be the most 
important predictors of access to medicines. Although the 
proportion of HSU obtaining a prescription and paying for 
drugs has broadly stayed the same as in 1994, the percentage 
of HSU paying for their prescribed medicines decreased from 
70% in 1994 to 42% at Ministry of Health institutions in 2006. 
Conclusion. The progress in prescription and population 
access to medicines has been uneven across health service 
providers. 
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Resumen
Objetivo. Analizar la prescripción médica, surtimiento de 
recetas y gasto en medicamentos que tienen los usuarios 
del primer nivel de los servicios de salud (UPNS) en 2006 
y evaluar su evolución en los últimos 12 años. Material 
y métodos. Utilizando los datos de la Encuesta Nacional 
de Salud de 2006 se construyeron tres modelos de regre-
sión logística para identificar los factores asociados con la 
prescrip ción, el surtimiento de medicamentos y el pago por 
medicamentos recetados. Se compararon los resultados del 
acceso a medicamentos con los de encuestas anteriores de 
1994 y 2000. Resultados. La variable más relevante para el 
acceso a medicamentos fue el tipo de institución donde se 
prestó atención. Aunque al nivel global la proporción de los 
UPNS que obtuvieron una prescripción y que pagaron por 
los medicamentos más o menos se mantuvo estable, el 
porcentaje de los UPNS que pagaron por los medicamentos 
en las instituciones de la Secretaría de Salud disminuyó de 
70 a 42% entre 1994 y 2006. Conclusión. El mejoramiento 
del acceso a medicamentos para usuarios de los servicios de 
salud ha sido desigual a través de las instituciones.
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Access to essential medicines in developing coun-tries is one of the indicators of the Millennium 
Development Goals, and it is considered fundamental 
to guarantee adequate health care and safeguard hu-
man rights.1 The World Health Organization (WHO) 
has defined access as equitable availability and afford-
ability of essential drugs and a key indicator for health 
care quality and their availability is a pre-requisite 
to provide effective care.2 Access can be measured in 
various ways; indicators proposed to measure access 
to medicines include among others prescription rate 
among health service users (HSU), the ability to obtain 
the prescribed medicines, percentage of HSU who have 
to pay for their prescribed medicines and amount of 
out-of-pocket expenditure on medicines.3
 In Mexico, like in many other developing countries, 
access to medicines has been hampered in various 
ways.4 On the one hand, stock-outs of medicines in 
public healthcare institutions are a chronic problem, in 
particular in those health services which provide care 
for the uninsured.5,6This seriously affects quality of care. 
Pharmaceutical policy in the last decade has focused on 
improving the availability of medicines in public health 
care institution.7 As a result, a presidential initiative was 
launched in 2002 to improve logistics and investment in 
the distribution chain of medicines.8However, since then 
independent evaluations of the situation of availability 
of medicines in public healthcare institutions have been 
of limited scope. 
 On the other hand, similarly to other developing 
countries, in Mexico there is a high out-of-pocket expen-
diture on medicines: a recent OECD report highlights 
that over 80% of drugs expenditures are out-of pocket, 
the highest proportion among the countries considered.9 
For the lowest income group 60% of the household 
expenditure has been attributed to medicines; and 66% 
of those health expenditures considered as “impoverish-
ing” – that is, deemed to push consumers below the pov-
erty line– was spent on medicines.10 Therefore, providing 
access to medicines by social security and public health 
care institutions is considered instrumental to guarantee 
sustainable access to medicines in the future. 
 Mexico’s health system is fragmented as in many 
Latin American countries. The main insurers are the one 
for employed workers (IMSS), the one for employees of 
governmental institutions (ISSSTE) and the Ministry of 
Health (Secretaría de Salud - SSA) Institutions for work-
ers from the informal sector or the unemployed. The 
social security institutions provide prescribed medicines 
free of charge at the point of care (no co-payment).11To 
uninsured individuals, the Ministry of Health provides 
medicines free of charge only for hospitalized patients. 
Medicines prescribed in ambulatory care (outpatient) 
are subsidized for uninsured individuals, and fees are 
inversely related to patients’ income.7 Whether ambula-
tory HSU in Ministry of Health facilities are required to 
pay the fee and the amount paid vary between states. 
 The structure of the health system has profoundly 
changed in the last decade. In 2002 a new insurance 
system, the People’s Health Insurance (Seguro Popular), 
was introduced offering health insurance for all those 
who were previously uninsured. One of the core objec-
tives of the program is to provide financial protection 
against catastrophic health care expenditures by provi-
sion a basic package of health services free of charge at 
the point of care. The basic package includes a core set of 
medicines. Since then more than 10 million individuals 
have been enrolled,12 with the objective to affiliate by 
2010 all individuals previously not covered by health 
insurance, about 50 million in 2002.11 Seguro Popular is 
a purchaser which contracts providers for the delivery 
of services, mostly Ministry of Health institutions which 
need to comply with a set of quality criteria in order to 
qualify as Seguro Popular service providers. As a result 
in 2006, in most states the Ministry of Health institutions 
provided care to those without health insurance and 
those with Seguro Popular, the later with the right to 
receive a defined list of essential medicines free at the 
point of care. 
 In Mexico, National Health Surveys (Encuesta 
National de Salud/Encuesta National de Salud y Nu-
tricion, ENSA/ENSANUT) have been carried out since 
1988 every six years. These are comprehensive surveys 
consisting of five different questionnaire: household, 
adults, young people, children and health service use. 
All of the questionnaires are applied at household level. 
The majority of questions related to medicines are in the 
health services use questionnaire and allows analyzing 
access to medicines for HSU. Comparison of subsequent 
survey results is feasible, since its core set of questions 
have not been changed over the years.
 In the light of the important changes in health policy 
in the last decade the objectives of the present research 
were: 1) to analyse the level of drug prescription, access 
to and expenditure for prescribed medicines by ambula-
tory health services users in 2006, and; 2) to evaluate its 
evolution in the last twelve years. 
Material and Methods
Design and sample size selection 
Data from three national health surveys were used for 
analysis: the ENSA 1994, 2000 and ENSANUT 2006.13,14, 
The surveys consisted of a cross-sectional, multi-stage, 
stratified random sample of households. 
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Data analysis 
On the basis of the WHO definition of access to medi-
cines and the suggested indicators for measuring it, 
four variables from the National Health Surveys were 
identified as suitable to analyze access: receiving a pre-
scription, obtaining the prescribed medicines, payment 
for medicines and finally, expenditure on medicines. 
 The prescription rate was defined for the three 
surveys in terms of the proportion of HSU who were 
prescribed any drug during an outpatient visit. The 
prescription filling rate was defined as the percentage of 
HSU with a prescription who were able to acquire the 
prescribed drugs regardless of payment. Payment for pre-
scribed medicines were defined as the proportion of HSU 
who reported paying for prescription drugs. Expenditure 
on medicines made in the consultation was defined as the 
amount of money spent on the purchased of the pre-
scribed medicines in Mexican pesos reported by HSU. 
The prescription filling rate was only calculated for 1994 
and 2006 surveys due the absence of this variable in the 
2000 National Health Survey instrument. Drug expen-
ditures per visit were analysed by their median value. 
In order to compare 1994, 2000 and 2006 expenditures, 
constant prices were calculated using a price deflator 
index with 1993 as a base year, as provided by the Bank 
of Mexico.15 Chi-square and Mann-Whitney tests were 
performed to check for difference of proportion across 
group results. 
 With the information from ENSANUT 2006, mul-
tivariate logit models were developed to find the main 
factors related to prescription, prescription filling and 
payment for prescribed medicines. The sample weight 
was used according the design for this analysis. Data 
were analysed per type of health service provider, 
patient characteristics and geographical location. Socio-
economic status, regions or ethnicity were of particular 
relevance to test for inequity in access to medicines. For 
instance, we were interested in inequity in receiving a 
prescription due to ethnicity or geographical region after 
adjusting for clinical factors such as age and disease 
severity. All the variables included in the models are 
explained in detail in the following.
Individual characteristics
Age was included as a categorical variable divided in 
four groups (0-4, 5-14, 15-44, 45 years and older), sex, 
ethnicity (indicator of indigenous) were included as 
binary variables. 
Household characteristics
Patients’ socio-economic groups were determined on the 
basis of their annual income and on the ownership of as-
sets such as house, car and other goods. The accessibility 
to the health facility can be affected by the region where 
the HSU lives. Five regions were defined according to 
geographical and political criteria: Northern, Central, 
Mexico City Metropolitan Area-ZMCM, Southeast-Gulf 
and areas benefiting of the social assistance programme 
for disadvantaged areas- PASSPA.* The reason to choose 
this division by regions was done first, to give tribute 
to the fact that Mexico has important regional varia-
tions with respect to socio-economic development and 
health service provision.16 Previous authors have used 
similar divisions which makes comparison with data 
from 1994 possible.17
Health care characteristics
The perception of the severity of the health problem 
was included in the model categorized as mild, mod-
erate or severe. The type of service provided was also 
taken into account classified as preventative, curative 
or other. Curative was used as reference category since 
it was expected that the prescription was higher in this 
type of service. The institutions providing care were 
classified as Social Security, Ministry of Health, those 
institutions which provide care for Seguro Popular 
affiliated (which will be called Seguro Popular for the 
purpose of this study), private providers, other public 
or private institutions (others). 
 For the first model, the dependent variable was 
specified with a value of 1 for being given a prescription 
and 0 otherwise. The second model had for dependent 
variable, no or incomplete prescription filling as 1 and 
0 if the patient received the prescribed medicines. In the 
third model the payment for medicines was analyzed 
giving the value of 1 if the patient had to pay for their 
medication and 0 otherwise. Results were expressed in 
* Northern: Baja Califórnia, Baja Califórnia Sur, Sonora, Chihuahua, 
Sinaloa, Coahuila, Nuevo León, Tamaulipas, Durango and Zacate-
cas. Central: San Luis Potosí, Guanajauto, Querétaro, Michoacán, 
México, Tlaxcala, Nayarit, Aguascalientes, Jalisco and Colima. 
ZMCM: Distrito Federal and metropolitan districts. PASSPA: Hidal-
go, Oaxaca, Guerrero and Chiapas. Southeast/Gulf: Morelos, Puebla, 
Veracruz, Campeche, Tabasco, Yucatán and Quintana Roo.
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terms of adjusted odds ratios with confidence intervals 
at 95% level. For the data analysis, the software SPSS 
version 14 was used.
 To evaluate the changes in prescription, prescription 
filling and expenditure the results from 2006 were com-
pared with the results of the National Health Surveys 
from 1994 and 2000. 
Results
Prescription and access to medicines in 2006
Prescription
In total, 11 721 of the 47 214 household members inter-
viewed in the 2006 National Health Survey reported 
having an ambulatory care visit in the last two weeks. 
Table I describes the frequency of those of who received 
a prescription, obtained their prescribed medicines and 
had to pay for them. There was no statistical difference 
of prescription rates between men and women, indig-
enous and non-indigenous HSU, or between education 
levels. Across types of health service providers, private 
hospitals and clinics as well as PEMEX and military 
institutions recorded the highest rate of prescription 
(>91%), while in Oportunidades hospitals and National 
Institutes the rate was approximately 75%.
 The percentage of those who were prescribed 
drugs during an outpatient visit ranged from the low-
est 76.5% in Hidalgo to the highest 93.1% in Tabasco 
and Campeche. By geographical regions, patients in 
the metropolitan area of Mexico City were prescribed 
drugs 89.9% of times, while those in the economically 
disadvantaged PASSPA states were given a prescrip-
tion in 84.5% of cases. This latter resulted statistically 
significant at p>0.001. 
 The results from the logistic regression appear to 
confirm the general picture from the descriptive statis-
tics, as they identify age, perception of the problem, the 
type of services and providers the main factors affecting 
prescription rates in their respective categories (Table II). 
For those seeking care in private health service provid-
ers, the odds ratio of receiving a prescription resulted 
almost twice as high as for those in the social security as 
reference category. The prescription rate was higher in 
Seguro Popular health service providers than in social 
security ones, meanwhile the lowest rate was found in 
the Ministry of Health service providers. Lower ages 
and curative services were the characteristics associated 
with receiving a prescription more frequently. 
Prescription filling
In terms of prescription filling, the overall proportion of 
patients who were prescribed and obtained their drugs 
was 95%, while 5% could only obtain some of the drugs 
or none at all. Only the health service provider was 
associated with prescription filling. Most importantly, 
users of Seguro Popular services were three times less 
able to obtain all the prescribed drugs (p=0.00; OR=3.61; 
95%CI = 2.31-5.62) and users of Ministry of Health 
services more than twice less likely (p=0.00; OR=2.25; 
95%CI=1.39-3.65) compared to HSU of social security 
institutions.
Payment
As for the proportion of HSU paying for medicines, 
about 47% of the patients surveyed reported paying 
for their prescribed drugs. Patients in PASSPA and 
Mexico City reported paying more frequently than 
others (55 and 58% respectively). Michoacan was the 
state where the highest percentage of HSU paying for 
their drugs (68%). The logistic regression model shows 
that the health service provider was one of the strongest 
predictor of payment (Table III). While social security 
services recorded by far the lowest probability of paying 
medicines, users of private health service providers paid 
frequently for their medicines. A large difference was 
detected between the odds ratio of the social security 
institutions, Seguro Popular and those of the Ministry of 
Health: the odds ratio for Seguro Popular was 4.8 times 
higher and 9 times higher for the Ministry of Health in 
comparison to the Social Security. Furthermore, more 
HSU who perceived their health problem as severe, 
who were younger and did not have medical insurance 
happened to pay for their medicines.
 Median drug expenditure per visit was $MX200, al-
though for those patients in the highest socio-economic 
group it was $MX300. Expenditures in Oportunidades 
health service facilities was the lowest ($121), and in 
PEMEX and State ISSSTE was the highest ($MX 360 
and 450). However, when adjusted by perception of the 
severity of the health problem it becomes apparent that 
HSU who perceived their problems as severe and visited 
private health service providers paid significantly more 
than the ones who visited Ministry of Health, Seguro 
Popular or other services (Figure 1). Median expenditure 
for medicines by Seguro Popular users was higher than 
compared to users of Ministry of Health facilities ($129 
versus $170 for mild to moderate health problems and 
Artículo originAl
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Table 1
Descriptive statistics eNsaNUt 2006 
Variables Frequency (%)n=11,721
Percentage (%) of HSU 
who received a prescrip-
tion n=10,285 
Percentage (%) of HSU 
who received their prescri-
bed medicines n= 9,786
Percentage (%) of HSU 
who had to pay for their 
medicines n=4,651
Sex
Male 4 551 (38.8) 39.4 39.4 41.4
Female 7 170 (61.2) 60.6 60.6 58.6
Age
<5 years 1 864 (15.9) 16.0 16.1 20.3
5-14 1 937 (16.5) 17.1 17.1 18.4
15-44 3 613 (30.8) 29.7 29.5 30.5
>45 4 307 (36.7) 37.2 37.3 30.
Educational level
Without education 1 064 (9.1) 10.9 11.0 11.0)
Primary 5 195 (44.3) 53.6 53.7 52.
Secondary 1 798 (15.3) 17.9 17.8 17.9
More than secondary 1 779 (15.2) 17.5 17.5 18.2
Indigenous
Yes 2 249 (19.2) 19.1 19.1 18.5
No 9 427 (80.4) 80.6 80.6 81.2
Without information 45 (0.4) 0.3   0.3 0.3
Socio-economic level
Very low 4 716 (40.2) 40.3 40.1 39.2
Low 2 437 (20.8) 20.8 20.8 20.9
Medium 3 295 (28.1) 28.4 28.5 28.5
High 1 272 (10.9) 10.5 10.6 11.5
Medical insurance
Yes 7 160 (61.1) 60.9 60.6 42.1
No 4 553 (38.8) 39.1 39.4 57.9
Type of service
Curative 8 170 (69.7) 74.0 74.3 75.1
Preventive 1 002 (8.5) 5.4 5.3 3.6
Other 2 546 (21.7) 20.6 20.3 21.3
Institution
Social Security 3 523 (30.1) 30.1 30.4 4.4
Ministry of Health 2 785 (23.2) 22.1 21.5 19.5
Seguro Popular 1 080 (9.2) 9.4 8.9 4.3
Other public 371 (3.2) 2.9 2.8 2.6
Private 3 627 (30.9) 33.3 34.3 65.6
Others 244 (2.1) 2.2 2.2 3.5
Region
PASPA 1 374 (11.7) 11.6 11.6 13.7
North 3 317 (28.3) 27.9 27.9 23.6
Center 4 116 (35.1) 35.0 34.9 36.3
Metropolitan Zone 410 (3.5) 3.6 3.6 4.4
Southeast/Golf 2 504 (21.4) 21.9 22.1 22.0
Perception of the problem
Mild 3 035 (40.2) 40.6 40.6 38.5
Moderate 2 585 (34.3) 34.5 34.4 34.5
Severe 1 921 (25.5) 24.9 25.0 27.0
$200 versus $290 for severe problems) although not 
statistically significant. 
Evolution of prescription, access and 
payment
When comparing data from 2006 with the National 
Health Surveys conducted in 1994 (HSU= 3 324) and 2000 
(HSU=53 383), prescription rates appear to have steadily 
increased by approximately 10% between 1994 and 2006. 
The proportion of patients who obtained their prescribed 
medicines did not change significantly. A similar propor-
tion of patients declared paying for their drugs in 1994 
and in 2006, about half of those surveyed.
 Median drug expenditures per visit went from $40 
in 1994 to $200 in 2006. Adjusting for inflation and GDP 
increase with 1993 prices as base year, median drug 
expenditures per outpatient visit at constant prices did 
not appear to change substantially from 1994 to 2006 
(Table IV).
 However, when breaking down results by health 
service providers, the proportion of patients who paid 
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for their medicines appeared to significantly decrease 
for Ministry of Health institutions (from 70 to 40%); 
for Social Security users the proportion did not change 
significantly, and the percentage of private providers 
users slightly increased (Figure 2). 
 In terms of patients paying for their medicines, in 
1994 and 2006 belonging to the poorest PASSPA region 
was statistically significantly associated with more fre-
quent payment for medicines by HSU; 48% of HSU in 
1994 paid for their prescribed drugs, but such proportion 
was the highest (59%) in the PASSPA region and the 
lowest (38%) in the Northern states17. The difference in 
proportion of paying patients between 2000 and 2006 
appeared particularly stark for the poorest PASSPA 
regions (50 and 58% respectively). 
 As for comparing drugs expenditures across socio-
economic groups, in 1994 approximately 56% of patients 
from the highest group but only 45% from the lowest 
one received their prescribed drugs free of charge. 
However, this changed in 2006 where the situation ap-
peared reversed. Less than half (49%) of patients from 
the highest SEC group, but 54% for those in the lowest 
income quartile got their prescribed medicines without 
payment (p=0.018).
 
Only those health service users who paid for their medicines were included 
in this analysis. 
Source: ENSANUT 2006
FigUre 1. MeDiaN DrUg expeNDitUres per type oF health 
service proviDer (Mx$) accorDiNg to the perceptioN 
oF the health probleM iN 2006
Table II
Factors associateD with receiviNg
a prescriptioN iN 2006
 Prescription
   Odds Lower Upper
Variable p-value ratio 95% IC 95% IC
Age (years)
 0-<5  1
 5-14 0.655 0.881 0.505 1.537
 15-44 0.011 0.580 0.381 0.882
 45 and over 0.018 0.599 0.392 0.917
Services
 Curative  1
 Preventive 0.000 0.282 0.161 0.494
 Other 0.000 0.414 0.295 0.581
Health service provider
 Social security  1
 Ministry of health 0.169 0.747 0.493 1.133
 Seguro Popular 0.149 1.467 0.871 2.469
 Private 0.024 1.695 1.072 2.681
 Others 0.480 0.765 0.364 1.609
Source: ENSANUT 2006
The model is adjusted for sex, indigenous, medical insurance, perception of 
the health problem, socio-economic level, geographical region; r=0.024
 Payment for prescribed medicines
   Odds Lower Upper
Variable p-value ratio 95% IC 95% IC
Age (years)
 0-<5  1
 5-14 0.001 0.575 0.410 0.805
 15-44 0.008 0.639 0.460 0.889
 45 and over 0.000 0.428 0.306 0.599
Perception of severity
 Mild  1
 Moderate 0.223 1.168 0.910 1.501
 Severe 0.000 1.697 1.294 2.225
 Medical insurance 0.000 0.471 0.369 0.601
Services
 Curative  1
 Preventive 0.163 1.575 0.832 2.984
 Other 0.000 1.789 1.355 2.364
 
Health service provider
 Social security  1
 Ministry of Health 0.000 10.705 7.252 15.803
 Seguro Popular 0.000 5.134 3.377 7.806
 Private 0.000 113.648 78.713 164.087
 Others 0.000 20.265 13.117 31.309
Source ENSANUT 2006; The model is adjusted by sex, indigenous, socio-
economic level, region. r=0.45
Table III
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Source: ENSA 1994, ENSA 2000 and ENSANUT 2006
FigUre 2. proportioN oF health services Users payiNg 
For their MeDiciNes by health service proviDer
Table IV
coMparisoN betweeN prescriptioN, prescriptioN FilliNg, payMeNt aND MeDiciNes expeNDitUre






Proportion of patients with drugs prescribed 78% 81% 86%
Proportion of patients who obtained their prescribed drugs 97% NA 95%
Patients who found all their prescribed drugs in the institution 61% NA 64%
Proportion of patients who had to buy drugs in private pharmacies 39% NA 27%
Proportion of patients who paid for their prescribed drugs 48% 42% 47%
Median drug expenditure per visit ($MX at current prices) 40 150 200
Drug expenditures at constant prices 37 44 40
Source: * ENSA II 1994
 ‡ ENSA 2000
 § ENSANUT 2006
private providers and the lowest in Ministry of Health. 
This should cast doubts on that the prescriptions are 
purely based on clinical needs, particularly the seem-
ingly high prescription filling rates in the private sector. 
Our findings appear to be in line with other authors’ 
analysis of the country’s health care system’s histori-
cal evolution,18 according to which the system would 
be highly fragmented and offering diverse quality of 
care according to the type of health service provider 
visited. 
 Overall, population access to medicines did not 
seem to have improved significantly over the years, as 
the proportion of HSU obtaining drugs in the institution 
of care or elsewhere broadly stayed the same as in 1994, 
just like the proportion of those paying for medicines. 
However, some reduction in inequality of access indica-
tors was visible in terms of the proportion of patients 
paying for drugs in the lowest socio-economic groups, 
although not specifically for the most disadvantaged 
regions. A possible interpretation of this finding is 
that change in access to drugs has been driven mostly 
through selected health service providers, rather than 
specifically targeting disadvantaged groups. In this way 
the reduction by nearly half from 70 to 42% of Minis-
try of Health services users who had to pay for their 
prescribed drugs is striking and can be considered an 
important finding in terms of equity and social protec-
tion policy. 
 In 2006 the median expenditure on medicines var-
ied according to perception of the severity of the health 
problem. However, in both cases the users of private 
health service providers had to pay significantly more 
Discussion
The analysis of the National Health Survey of Mexico 
provide important data on prescription rate, prescrip-
tion filling and payment for medicines by ambulatory 
HSU over the last 12 years which are highly relevant for 
health policy making. 
 The results from our analysis showed that type of 
health service provider is the most relevant predictors 
of access to drugs for ambulatory HSU in Mexico. It 
was striking that prescription rates were the highest in 
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than HSU of other providers. When taking inflation into 
account, overall median drug expenditures per visit in 
2006 appear to have only marginally increased with 
respect to 1994. Nonetheless when relating such cost to 
a proxy of the population ability to pay, it emerges that 
in 1994 the median drug expenditure represented 2.7 
times of the daily minimum salary (40 Mexican pesos), 
but as much as 4.1 times the daily minimum salary (200 
Mexican pesos) in 2006.19 A possible interpretation of 
such calculation is that, as nominal prices of medicines 
increased steadily over the last decade, real wages failed 
to keep pace; the most affected by such situation are 
likely to be those on minimum wage, supposedly at the 
lower end of the income distribution. 
 Seguro Popular affiliated paid less frequently than 
other Ministry of Health users. This is an important 
achievement, taking into account that one of the key 
objective of this new insurance program is to protect 
against catastrophic health care expenditure. However, 
Seguro Popular affiliated more frequently did not ob-
tain some or all of the prescribed medicines and pay 
more frequently for medicines than their peer users in 
social security institutions. Furthermore, the median 
expenditure they spend on medicines appears to be 
higher than Ministry of Health users which means that 
Seguro Popular has not achieved fully its objectives. To 
this respect, further research is required to understand 
what medicines Seguro Popular patients happen to pay 
more, in order to evaluate available policy options, such 
as amplifying the current drug formulary or improving 
prescribing practice of physicians.
 The principal limitation of the data used in our 
research is that the National Health Surveys only cover 
access to medicines among ambulatory HSU and not 
those who do not seek institutional care. In Mexico 
self-medication is frequent; data from ENSA 2000 show 
that around one third of individuals (30.5%) who had a 
health problem in the last two weeks self-medicated.20 In 
addition, the surveys did not collect information on type 
of drugs supplied; this made it impossible to analyze 
prescription patterns and to fully appreciate the extent 
to which provision of drugs in Mexico has changed over 
the years. Furthermore, the 2000 ENSA survey did not 
include questions on the proportion of patient actually 
obtaining the prescribed drugs in the institutions vis-
ited or elsewhere. This latter limited our analysis of the 
changes of access to drugs over the years. 
Conclusions
Despite the limitations of the data available, the present 
research contributes in a number of ways to the existing 
body of knowledge on prescription, prescription filling 
and payment for medicines in low and middle-income 
countries. First of all, the study shows that in Mexico the 
vast majority of HSU receive a prescription, although 
only half of them free of charge. Secondly, the type 
of provider is an important predictor of prescription, 
prescription filling and payment. 
 Although prescription rates appear to have in-
creased steadily, in terms of payment, the overall situ-
ation did not appear to have changed significantly in 
the last 12 years. However, improvement is visible for 
users of Ministry of Health and Seguro Popular provid-
ers, where the proportion of users paying for medicines 
has fallen considerably. Given the Government’s effort 
and resources devoted to reducing inequalities in health 
service utilisation, further evaluation is needed to assess 
the impact and cost-effectiveness of its action. Without 
any doubt, understanding better these aspects would 
help design more effective policies, as well as allocate 
scarce health resources across those programmes poised 
to yield the highest value for tax-payers’ money.
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